Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

Oncocyte Unveils Breakthrough Liquid Biopsy for Brain Tumor Diagnostics with DetermaCNI™

NextEdge Admin

05 Dec 2024

2 min 16 sec

Oncocyte Corporation (NASDAQ: OCX), a diagnostics technology leader, announced the publication of favorable data for its DetermaCNI™ assay in Acta Neuropathologica Communications. The study highlights DetermaCNI’s potential as a liquid biopsy method for diagnosing and profiling central nervous system (CNS) tumors via somatic copy number aberrations (SCNAs) in cerebrospinal fluid (CSF).

DetermaCNI™, which measures copy number instability (CNI), a hallmark of cancer, could address a critical need for the nearly 300,000 U.S. patients diagnosed annually with primary brain tumors or brain metastases. Current diagnostics rely on invasive tissue biopsies that pose risks and limited sensitivity. In this study, SCNAs were detected in 10 of 12 patients with CNS cancers, with no SCNAs found in 11 patients with benign or unclear CNS lesions, demonstrating high tumor specificity.

Dr. Ekke Schuetz, Oncocyte’s Chief Science Officer, stated, “This proof-of-principle study suggests DetermaCNI™ could provide significant benefits for patients with brain tumors by enabling molecularly informed diagnoses through a minimally invasive liquid biopsy.”

This assay could offer advantages in tumor classification, heterogeneity mapping, and evolution tracking. Oncocyte views these results as a validation of its R&D efforts and pipeline direction. Alongside its VitaGraft™ and GraftAssure™ transplant tests, Oncocyte plans to commercialize its oncology assays, including DetermaCNI™, within two years to improve patient outcomes and advance molecular diagnostics access.

The study underscores a $300M market opportunity, aiming to revolutionize CNS cancer care.